Arcus Biosciences, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Terry J. Rosen
- Full Time Employees
- 601
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3928 Point Eden Way Hayward CA United States of America 94545
- IPO Date
- Mar 14, 2018
- CIK
- 0001724521
- Website
- arcusbio.com
- Similar Companies
- Business
- Arcus Biosciences, Inc. is a clinical-stage global biopharmaceutical company focused on developing differentiated molecules and combination therapies primarily for cancer treatment. The company’s core products include investigational medicines targeting immune checkpoints and tumor microenvironment pathways. Key programs consist of domvanalimab (anti-TIGIT antibody); zimberelimab (anti-PD-1 antibody); quemliclustat (a CD73 inhibitor); and casdatifan (AB521), a selective HIF-2α inhibitor targeting clear cell renal cell carcinoma (ccRCC). Arcus leverages innovative antibody engineering and synthetic biology platforms to develop its pipeline of immuno-oncology and chronic disease therapeutics. Founded in 2015 and headquartered in Hayward, California, Arcus operates globally with clinical trials and research collaborations internationally. Its strategic focus is on cancer immunotherapy, aiming to restore immune response by overcoming tumor-induced immunosuppression. The company also explores treatments for inflammatory conditions and autoimmune diseases. Arcus has a substantial financial position, bolstered by a $250 million loan facility from Hercules Capital and more than $1 billion in cash and marketable securities as of mid-2024, enabling advancement of its clinical pipeline. Recent major developments include the initiation of the Phase 3 PEAK-1 study evaluating casdatifan in combination with cabozantinib versus cabozantinib alone in patients with IO-experienced ccRCC, expected to start in 2025. Arcus also has a collaboration with AstraZeneca to study casdatifan plus AstraZeneca’s anti-PD-1/CTLA-4 bispecific antibody in IO-naive ccRCC patients. Additionally, Arcus regained full developmental and commercial rights to casdatifan after Gilead Sciences' option period expired in early 2025, which marked a strategic shift allowing independent advancement of this key asset. Gilead Sciences remains a significant equity holder and strategic partner, having increased its investment and board representation in Arcus. The company also plans to launch additional Phase 3 trials and continues to evaluate its clinical programs to optimize the development of multiple pipeline assets. Arcus Biosciences’ product portfolio targets key immune regulatory pathways with an emphasis on combination immunotherapies for cancer, including PD-1, TIGIT, and the adenosine axis. Its pipeline candidates are in various stages of clinical development, with particular emphasis on therapies for solid tumors such as metastatic colorectal cancer, pancreatic cancer, and ccRCC. The company’s strategic alliances, robust financial backing, and advanced therapeutic platforms position it for progression toward potential regulatory approvals and commercialization in the mid-term future. Overall, Arcus Biosciences is a clinical and translational biopharmaceutical company advancing innovative oncology therapies through a comprehensive pipeline of antibody-based and molecular targeted agents, supported by powerful collaborations and a solid financial foundation from its founding in 2015 through 2025.
Company News
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Q2 Earnings Call Highlights
Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Arcus Biosciences Announces New Employment Inducement Grants
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
Arcus Biosciences Announces New Employment Inducement Grants
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript